Authors
D Nakajima, M Cypel, R Bonato, TN Machuca, I Iskender, K Hashimoto, V Linacre, M Chen, R Coutinho, S Azad, T Martinu, TK Waddell, DM Hwang, S Husain, M Liu, S Keshavjee
Publication date
2016/4/1
Journal
American Journal of Transplantation
Volume
16
Issue
4
Pages
1229-1237
Publisher
Elsevier
Description
Ex vivo lung perfusion (EVLP) is a platform to treat infected donor lungs with antibiotic therapy before lung transplantation. Human donor lungs that were rejected for transplantation because of clinical concern regarding infection were randomly assigned to two groups. In the antibiotic group (n = 8), lungs underwent EVLP for 12 h with high-dose antibiotics (ciprofloxacin 400 mg or azithromycin 500 mg, vancomycin 15 mg/kg, and meropenem 2 g). In the control group (n = 7), lungs underwent EVLP for 12 h without antibiotics. A quantitative decrease in bacterial counts in bronchoalveolar lavage (BAL) was found in all antibiotic-treated cases but in only two control cases. Perfusate endotoxin levels at 12 h were significantly lower in the antibiotic group compared with the control group. EVLP with broad-spectrum antibiotic therapy significantly improved pulmonary oxygenation and compliance and reduced pulmonary …
Total citations
20162017201820192020202120222023202471728132816191312
Scholar articles
D Nakajima, M Cypel, R Bonato, TN Machuca… - American Journal of Transplantation, 2016